Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for schizophrenia
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Necessity of oral health intervention in schizophrenic patients - A review Individuals with mental illness often cannot perform day to day activities due to a psychiatric or emotional disorder. Schizophrenia is one such psychiatric disorder characterized by worsening self-care ability with progressing mental illness. This disease may potentially deteriorate oral health by affecting the subject's ability to perform oral hygiene measures. Literature on oral disease manifestations in schizophrenia (...) is limited. Lack of desire for oral health care as well as generally poor awareness of oral health issues in these patients, compounded further by side effects of medications, may complicate dental management in schizophrenic patients. The present review explores clinical features and possible factors associated with oral health status among those with Schizophrenia.
[Schizophrenia and informed consent to research]. Informed consent to research remains a complex issue, while sometimes staying difficult to obtain, even in the general population. This problem may be maximized with patients suffering from schizophrenia.This paper summarizes available data in the literature about informed consent for research involving patients suffering from schizophrenia.Medline and Google Scholar searches were conducted using the following MESH terms: schizophrenia, informed (...) consent and research.Studies using dedicated standardized scales (e.g. MacCAT-CR) revealed a decrease in the capacity to consent of patients with schizophrenia when compared with healthy individuals. Keeping in mind that schizophrenia is an heterogeneous disorder, patients with the lowest insight as well as those with the most severe cognitive symptoms appeared more impaired in their capacity to consent. Such a poor capacity to understand and consent to trials was shown linked with alterations
29 Year Old Man with Multiple Sclerosis and Schizophrenia: A Case Report Multiple sclerosis (MS) is the most common debilitating neurological disease that affects adults, whether young adults or middle-aged. Although, most attention is toward the neurological signs of the disease, the neuropsychiatric signs are not uncommon. This case report presents a 29 year old male with a record of obsessive-compulsive disorder (OCD) without psychotic disorder, which coincides with the diagnosis MS, has (...) of schizophrenia which was confirmed in subsequent visits. The signs of the patient were not controllable for a long time and finally fully controlled by a combination of Aripiprazole (abilizol), Risperidone and Sertraline, and currently, for almost 3 years, both psychotic symptoms and MS disease have been under control. Our patient seems to catch the MS disease and schizophrenia simultaneously. There was no relation between MS and psychosis episodes and the MS attacks. Since the onset the patient had several
Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report There is currently limited experience in the initiation and maintenance of clozapine for treatment-resistant psychosis in adults with established structural heart disease. These complex patients require close supervision and liaison between colleagues. Here we present the successful experience of treating one such patient within our service and describe a monitoring plan to ensure (...) that these treatments can be provided both safely and effectively.A 36-year-old man with treatment-resistant schizophrenia and known hypertrophic cardiomyopathy (HCM) was admitted to a specialist unit for a trial of clozapine. His psychiatric illness was characterised by multimodal hallucinations and delusions combined with low mood and poor motivation. The diagnosis of HCM was made 3 years previously following a routine electrocardiogram (ECG), and he had remained asymptomatic throughout this time; there were
Integrated supported employment plus cognitive remediation training for people with schizophrenia. 26908337 2016 12 13 2016 12 30 1024-2708 22 Suppl 2 2016 Feb Hong Kong medical journal = Xianggang yi xue za zhi Hong Kong Med J Integrated supported employment plus cognitive remediation training for people with schizophrenia. S15-8 Tsang H W H HW Neuropsychiatric Rehabilitation Laboratory, Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hong Kong. Bell M D MD (...) methods Employment, Supported methods Executive Function Female Hong Kong Humans Male Middle Aged Psychiatric Status Rating Scales Schizophrenia rehabilitation Social Skills 2016 2 25 6 0 2016 2 26 6 0 2016 12 15 6 0 ppublish 26908337
Valproate for schizophrenia. Many people with schizophrenia do not achieve a satisfactory treatment response with ordinary antipsychotic drug treatment. In these cases, various add-on medications are used, and valproate is one of these.To examine whether:1. valproate alone is an effective treatment for schizophrenia and schizoaffective psychoses; and2. valproate augmentation of antipsychotic medication is an effective treatment for the same illnesses.We searched the Cochrane Schizophrenia (...) Group's Study-Based Register of Trials (July 2002; February 2007; July 2012; March 04, 2016). We also contacted pharmaceutical companies and authors of relevant studies in order to identify further trials.We included all randomised controlled trials comparing valproate to antipsychotics or to placebo (or no intervention), whether as the sole agent or as an adjunct to antipsychotic medication for the treatment of people with schizophrenia or schizophrenia-like psychoses.We independently inspected
Contribution of oxytocin receptor polymorphisms to amygdala activation in schizophrenia spectrum disorders Oxytocin has been proposed to mediate amygdala dysfunction associated with altered emotion processing in schizophrenia, but the contribution of oxytocin pathway genes is yet to be investigated.To identify potential different contributions of three oxytocin receptor polymorphisms (rs53576, rs237902 and rs2254298) between patients with schizophrenia spectrum disorders (SCZ), affective
Effect of transcranial direct current stimulation (tDCS) over the prefrontal cortex combined with cognitive training for treating schizophrenia: a sham-controlled randomized clinical trial. We report a transcranial direct current stimulation (tDCS) protocol over the dorsolateral prefrontal cortex (DLPFC) combined with cognitive training in schizophrenia.We assessed psychotic symptoms in nine patients using the Positive and Negative Syndrome Scale (PANSS). All evaluations were scored at baseline (...) severity scores (p = 0.619). Mixed analysis of variance (ANOVA) showed no statistical significance between the groups regarding final PANSS scores.The results failed to demonstrate that the concomitant use of tDCS and cognitive training is effective to improve clinical outcomes in patients with schizophrenia. The present findings should be analyzed with care, considering the small sample size. Larger controlled trials on electric/cognitive stimulation should be produced in order to enhance therapeutic
Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials. For treatment of patients diagnosed with schizophrenia, comparative long-term effectiveness of antipsychotic drugs to reduce relapses when minimising adverse effects is of clinical interest, hence prompting this review.To evaluate the comparative long-term effectiveness of antipsychotic drugs.We systematically searched electronic databases for reports of randomised (...) controlled trials (RCTs) of antipsychotic monotherapy aimed at reducing relapse risks in schizophrenia. We conducted network meta-analysis of 18 antipsychotics and placebo.Studies of 10 177 patients in 56 reports were included; treatment duration averaged 48 weeks (range 4-156). Olanzapine was significantly more effective than chlorpromazine (odds ratio (OR) 0.35, 95% CI 0.14-0.88) or haloperidol (OR=0.50, 95% CI 0.30-0.82); and fluphenazine decanoate was more effective than chlorpromazine (OR=0.31, 95
Treatment of clozapine-associated obesity and diabetes with exenatide (CODEX) in adults with schizophrenia: study protocol for a pilot randomised controlled trial. Clozapine causes significant metabolic disturbances including obesity and type 2 diabetes. Recent evidence that reduced glucagon-like-peptide-1 (GLP-1) may contribute to aetiology of clozapine-associated metabolic dysregulation suggests a potential therapeutic role for GLP-1 agonists.This open-label, pilot randomised controlled trial (...) evaluates the effect of exenatide in clozapine-treated obese adults who have schizophrenia, with or without poorly controlled diabetes. Sixty out-patients will be randomised to once weekly extended release exenatide or treatment as usual for 24 weeks.To evaluate the feasibility of larger studies regarding methodology, acceptability, tolerability and estimate efficacy for glycaemic control or weight loss. Secondary outcomes are psychosis severity and metabolic parameters.This is the first trial
Psychiatric symptoms in individuals who use ketamine versus methamphetamine-implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study. Psychiatric symptoms in individuals who use ketamine versus methamphetamine—implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study - The Lancet Go search This Journal Full Site Access provided by , S67, October 01, 2016 Powered By Mendeley Psychiatric symptoms in individuals who use ketamine versus (...) methamphetamine—implications for glutamatergic and dopaminergic model for schizophrenia: a cohort study Yanhui Liao Affiliations Mental Health Institute of the Second Xiangya Hospital, Central South University, Hunan 410011, China National Clinical Research Center on Mental Disorders & National Technology Institute on Mental Disorders, Hunan 410011, China Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan 410011, China Chang Qi Affiliations Mental Health Institute of the Second Xiangya
WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia. Risperidone is one of a number of 'atypical antipsychotics' which are currently being marketed for the treatment of those with schizophrenia, largely on the basis of claims of improved tolerability and effectiveness compared to much cheaper conventional antipsychotics. The efficacy of risperidone has already been compared to conventional drugs, but it remains unclear how risperidone compares with other (...) atypical antipsychotic drugs such as clozapine.To determine the effects of risperidone compared with other atypical antipsychotic drugs for schizophrenia.Electronic searches of Biological Abstracts (1980-1999), The Cochrane Library (Issue 1, 2000), The Cochrane Schizophrenia Group's Register (January 1999), EMBASE (1980-1999), MEDLINE (1966-1999), LILACS (1982-1999), PSYNDEX (1977-1999) and PsycLIT (1974-1999) were undertaken. In addition, pharmaceutical databases on the Dialog Corporation Datastar
Effect of Adjunctive Raloxifene Therapy on Severity of Refractory Schizophrenia in Women: A Randomized Clinical Trial A substantial proportion of women with schizophrenia experience debilitating treatment-refractory symptoms. The efficacy of estrogen in modulating brain function in schizophrenia has to be balanced against excess exposure of peripheral tissue. Raloxifene hydrochloride is a selective estrogen receptor modulator (mixed estrogen agonist/antagonist) with potential psychoprotective (...) effects and fewer estrogenic adverse effects.To determine whether adjunctive raloxifene therapy reduces illness severity in women with refractory schizophrenia.This 12-week, double-blind, placebo-controlled, randomized clinical trial with fortnightly assessments was performed at an urban tertiary referral center and a regional center from January 1, 2006, to December 31, 2014. Participants included 56 women with schizophrenia or schizoaffective disorder and marked symptom severity despite substantial
Experiences of medication adherence among people with schizophrenia: a systematic review protocol of qualitative evidence. The objective of this qualitative review is to synthesize the lived experiences of medication adherence among people with schizophrenia. The specific review question is: what are the experiences of taking prescribed medication among people with schizophrenia?
Olanzapine (ZypAdhera) - maintenance treatment of adult patients with schizophrenia Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1516: Olanzapine (ZypAdhera ® ) 210 mg, 300 mg, and 405 mg, powder and solvent for prolonged release suspension for injection. June 2016. Final Appraisal Recommendation Advice No: 1516 – June 2016 Olanzapine (...) of patients/patient carers (where available) and the lay member perspective. This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review every three years. Recommendation of AWMSG Olanzapine (ZypAdhera ® ) is recommended as an option for restricted use within NHS Wales. Olanzapine (ZypAdhera ® ) is licensed for the maintenance treatment of adult patients with schizophrenia sufficiently stabilised during acute treatment with oral olanzapine